You are here

Regeneron

Novartis sues Regeneron over manufacturing methods

Novartis sues Regeneron over manufacturing methods

Biopharma Dive

drug manufacturing

Flag link:

Regeneron, Alnylam partner to turn discovery into new drugs for NASH

Regeneron, Alnylam partner to turn discovery into new drugs for NASH

Biopharma Dive

Flag link:

Regeneron’s Eylea Shows Promise in Late-Stage Diabetic Retinopathy Trial

Regeneron’s Eylea Shows Promise in Late-Stage Diabetic Retinopathy Trial

Xtalks

diabetic retinopathy

Flag link:

With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell

With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell

Endpoints

Flag link:

Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar

Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar

Fierce Pharma

Flag link:

Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?

Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?

Yahoo/Reuters

clinical trials

Flag link:

Regeneron to Slash Price of Cholesterol Drug After Showing it Saved Lives

Regeneron to Slash Price of Cholesterol Drug After Showing it Saved Lives

Xconomy

Flag link:

Here's What Weighed on Regeneron Pharmaceuticals Inc. in February

Here's What Weighed on Regeneron Pharmaceuticals Inc. in February

Motley Fool

Flag link:

Regeneron vision drug Eylea sees upward tick in unexplained side-effect cases

Regeneron vision drug Eylea sees upward tick in unexplained side-effect cases

Fierce Pharma

Flag link:

The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs

The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs

Forbes

PCSK9 inhibitors

Flag link:

Regeneron’s coming late to a group of drugs that’s already worth billions — here’s why the company thinks it can still compete

Regeneron’s coming late to a group of drugs that’s already worth billions — here’s why the company thinks it can still compete

SF Gate, CA

PDL-1 inhibitors

Flag link:

Racing to replace opioids, biopharma is betting on pain drugs with a checkered past

Racing to replace opioids, biopharma is betting on pain drugs with a checkered past

Stat

Flag link:

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Fierce Pharma

Flag link:

JPM18: Regeneron, Sanofi boost I/O investment

JPM18: Regeneron, Sanofi boost I/O investment

Biopharma Dive

immuno-oncology

Flag link:

Sanofi and Regeneron boost investment in cancer drug cemiplimab

Sanofi and Regeneron boost investment in cancer drug cemiplimab

Yahoo/Reuters

Flag link:

Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar

Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar

Drug Delivery Business News

Momenta Pharmaceuticals

diabetic macular edema

wet age-related macular degeneration

Flag link:

On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo

On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo

Endpoints

cervical cancer

head and neck cancer

Flag link:

Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?

Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?

Motley Fool

Flag link:

Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?

Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?

Endpoints

advanced cutaneous squamous cell carcinoma

Flag link:

Regeneron CEO Schleifer, a year after public Pfizer spat, slams Allergan for tribal deal

Regeneron CEO Schleifer, a year after public Pfizer spat, slams Allergan for tribal deal

Fierce Pharma

Leonard Schleifer

Flag link:

Pages